Fischer Medical Ventures Ltd
Incorporated in 1993, Fischer Chemic Ltd does trading of chemicals and machineries[1]
- Market Cap ₹ 4,276 Cr.
- Current Price ₹ 799
- High / Low ₹ 841 / 413
- Stock P/E 1,909
- Book Value ₹ 15.2
- Dividend Yield 0.00 %
- ROCE 5.25 %
- ROE 4.55 %
- Face Value ₹ 10.0
Pros
- Company is almost debt free.
Cons
- Stock is trading at 52.5 times its book value
- Earnings include an other income of Rs.1.42 Cr.
- Company has high debtors of 398 days.
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Quarterly Results
Consolidated Figures in Rs. Crores / View Standalone
Profit & Loss
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2023 | Mar 2024 | TTM | |
|---|---|---|---|
| 0.18 | 20.98 | 82.32 | |
| 0.16 | 19.12 | 78.98 | |
| Operating Profit | 0.02 | 1.86 | 3.34 |
| OPM % | 11.11% | 8.87% | 4.06% |
| 0.00 | 0.50 | 1.42 | |
| Interest | 0.02 | 0.07 | 0.30 |
| Depreciation | 0.00 | 0.18 | 1.31 |
| Profit before tax | 0.00 | 2.11 | 3.15 |
| Tax % | 12.80% | ||
| -0.04 | 1.84 | 2.47 | |
| EPS in Rs | -2.33 | 0.34 | 0.46 |
| Dividend Payout % | 0.00% | 0.00% |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| TTM: | 11556% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| TTM: | 4700% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | 73% |
| 5 Years: | 70% |
| 3 Years: | 97% |
| 1 Year: | 97% |
| Return on Equity | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| Last Year: | 5% |
Balance Sheet
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2023 | Mar 2024 | Sep 2024 | |
|---|---|---|---|
| Equity Capital | 0.17 | 53.50 | 53.50 |
| Reserves | -0.44 | 27.61 | 27.95 |
| 0.57 | 1.68 | 1.47 | |
| 0.05 | 3.53 | 57.80 | |
| Total Liabilities | 0.35 | 86.32 | 140.72 |
| 0.00 | 14.71 | 14.87 | |
| CWIP | 0.00 | 0.00 | 2.89 |
| Investments | 0.00 | 1.21 | 11.70 |
| 0.35 | 70.40 | 111.26 | |
| Total Assets | 0.35 | 86.32 | 140.72 |
Cash Flows
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2023 | Mar 2024 | |
|---|---|---|
| -7.59 | ||
| -28.61 | ||
| 37.11 | ||
| Net Cash Flow | 0.91 |
Ratios
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2023 | Mar 2024 | |
|---|---|---|
| Debtor Days | 344.72 | 397.88 |
| Inventory Days | ||
| Days Payable | ||
| Cash Conversion Cycle | 344.72 | 397.88 |
| Working Capital Days | 324.44 | 505.40 |
| ROCE % | 5.25% |
Documents
Announcements
- Disclosures under Reg. 29(2) of SEBI (SAST) Regulations, 2011 1d
-
Update On Receipt Of Disclosure Under Regulation 29(2) Of SEBI (SAST), 2015
2d - Disclosure of substantial acquisition of shares by promoters.
- Disclosures under Reg. 29(2) of SEBI (SAST) Regulations, 2011 18 Feb
-
Board Meeting Outcome for Allotment Of Equity Shares And Warrants
18 Feb - Approval for allotment of equity shares and warrants.
-
Announcement Under Regulation 30 - Incorporation Of Subsidiary Company
15 Feb - Incorporation of Nanyang Biologics (India) Private Limited.
Annual reports
-
Financial Year 2024
from bse
-
Financial Year 2023
from bse
-
Financial Year 2022
from bse
-
Financial Year 2021
from bse
-
Financial Year 2020
from bse
-
Financial Year 2019
from bse
-
Financial Year 2018
from bse
-
Financial Year 2017
from bse
-
Financial Year 2016
from bse
-
Financial Year 2015
from bse
-
Financial Year 2014
from bse
-
Financial Year 2013
from bse
-
Financial Year 2012
from bse
-
Financial Year 2011
from bse
-
Financial Year 2010
from bse
Concalls
-
Dec 2024TranscriptNotesPPT
Business Overview:[1]
Company is in the business of processing, manufacturing and trading of Laboratory Grade Chemicals